Commercialising Disruptive Technology

Phacilitate
Georgi Makin
2 October 2020
SHARE NOW

This panel aired live at Phacilitate’s first virtual event, Advanced Therapies Connect and examined the role of disruptive technology in commercialising advanced therapies.

The panellists review the whole journey from the back of the napkin to the bedside.

Here’s your panel line up:

  • Kevin Alessandri, CEO/CTO, Treefrog Therapeutics
  • Vincent Ronfard, Chief Innovation Officer, CUTISS
  • Rob Schutte, Executive Director, Process Development, Humacyte
  • David Hodl, Vice President, Business Development, Cell Therapy, Invetech

Join the Phacilitate network and enjoy 100s of insight packed articles and videos.

Already a member?
Sign In